secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001493152-25-006040
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals announces study on avian flu prevention in poultry using water-based antiviral solution
--------------------------------------------------------------------------------

- Engaged Vipragen Biosciences for efficacy studies on H5N1 prevention via drinking water solution.
- Phase I animal studies showed significant reduction in lung viral load; Phase II ongoing.
- Solution uses GRAS ingredients; aims to offer non-pharmaceutical preventive tool.
- Avian flu outbreak led to culling of >148M birds in U.S. since 2022; egg prices hit $4.15/dozen Dec 2024.
- Global poultry market projected at $375.41B by 2030; company to share final study results upon completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225006040/0001493152-25-006040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225006040/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer